RATIONAL TARGETING OF PROTEIN KINASES IN PEDIATRIC LEUKEMIA: MECHANISMS, PATHOGENESIS AND INHIBITORY POTENTIAL OF THIENO[3,2 d]PYRIMIDINE DERIVATIVES
Astanakulova G. . & Buronov A. .
Annotatsiya
Pediatric leukemia, particularly acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML), remains a leading cause of cancer associated childhood mortality worldwide due to dysregulated signal transduction and unchecked proliferation of leukemic cells. Protein kinases, including BCR ABL1, CDKs (cyclin dependent kinases) and PI3K isoforms, play pivotal roles in leukemogenesis by modulating cell cycle progression, transcriptional control, and survival signaling. Targeted inhibition of these kinases has transformed leukemia therapy, such as tyrosine kinase inhibitors for chronic myeloid leukemia. In this study, we present a structure based design, synthesis and in silico evaluation of novel thieno[3,2 d]pyrimidine derivatives engineered to engage multiple leukemia associated kinase targets. Molecular docking and dynamics suggest stable engagement with key functional residues, indicating potential for selective inhibition of leukemia pathways. These findings provide a mechanistic rationale supporting further preclinical evaluation of thieno[3,2 d]pyrimidine modulators for pediatric leukemia therapy.
Adabiyotlar
- Kota JS, et al. Targeting acute myeloid leukemia by dual inhibition of PI3K signaling and Cdk9-mediated Mcl-1 transcription. Blood. 2013;122(5):738–748.
- Minzel W, Venkatachalam A, Fink A, et al. Small molecules co-targeting CKIα and the transcriptional kinases CDK7/9 control AML in preclinical models. Cell. 2018;175(1):171–185.
- Boffo S, Damato A, Alfano L, Giordano A. CDK9 inhibitors in acute myeloid leukemia. J Exp Clin Cancer Res. 2018;37(1):36.
- Chapuis N, Tamburini J, Green AS, et al. Targeting PI3K/AKT/mTOR pathway in AML: implications for therapy. Leukemia. 2010;24(5):798–805.
- Park S, Chapuis N, Tamburini J, et al. Dual targeting of PI3K and mTOR in AML. Clin Cancer Res. 2008;14(17):532–540.
- Alvocidib Investigator Group. Clinical and preclinical activities of alvocidib (flavopiridol) in AML. Leukemia Res. 2015;39:1312–1318.
- Yin T, Lallena MJ, Kreklau EL, et al. A novel CDK9 inhibitor shows potent antitumor efficacy in preclinical hematologic tumor models. Mol Cancer Ther. 2014;13(6):1442–1454.
- Parry D, Guzi T, Shanahan F, et al. Dinaciclib (SCH 727965), a novel CDK inhibitor with potent activity in leukemia models. Mol Cancer Ther. 2010;9(9):2344–2353.
- Walsby E, Pratt G, Shao H, et al. Novel Cdk9 targeting strategies synergize with conventional AML therapies. Oncotarget. 2014;5(8):375–385.